Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières.

Slides:

Advertisements

Similar presentations

2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006.

Advertisements

The WTO TRIPS Agreement, Innovation and Access to Medicines Does the emperor have any clothes at all? HAI Europe 25th Anniversary Conference, Oct 26 -

Ellen t Hoen, MSF Høsbjør, 8-11April 2001, WHO-WTO Workshop Differential Pricing 1 WHO-WTO Workshop Differential Pricing and Financing of Essential Drugs.

HINARI/Health Information on the Internet (module 1.3 Part B)

1 CHAI ARV Procurement Database Clinton Foundation HIV/AIDS Initiative November 7, 2005.

Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines.

ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.

Patent Pools Increasing access to Medicines and Innovation Ellen ‘t Hoen MSF Access to Essential Medicines Campaign Barcelona 9 Dec

Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.

Penn’s Innovations and the Global Poor Facilitating Access to Medicines in Developing Countries Universities Allied for Essential Medicines 22 Mar 2006.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

The global patent system & access to essential drugs Prof. dr. Sigrid Sterckx Ghent University Free University of Brussels.

Designing Strategies for Neglected Disease Research Lecture 1A Amy Kapczynski UC Berkeley Law From MSF Campaign for Access to Essential Medicines, AccessNews.

Nathan Trayner 1,2 ; John Prensner 1,2 ; Heather Ames 1,2 ; Ashwin Vasan 1,2 1.MD Candidate, University of Michigan Medical School 2.Universities Allied.

EU-India Free Trade Agreement: What future for patients in developing countries Tido von Schoen-Angerer Médecins Sans Frontières - Access to Essential.

Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.

Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.

Solutions: UAEM’s Framework for Advancing University Policy, Changing Practices & Closing the Research Gap Michael Lin and Gloria Tavera UAEM National.

1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.

Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.

Access to Essential Medicines and Intellectual Property Rights in Developing Countries Rachel M. Cohen Access to Essential Medicines Campaign Doctors Without.

Physicians and Health Care Workers’ Role in Conflict Zones Challenges and Successes Babak Abbaszadeh March 27, 2010, Ottawa.

Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.

They need new drugs, vaccines and diagnosis now: reality of neglected diseases Bernard Pecoul Executive Director, DNDi Geneva 7 December 2005.

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

International IP Regime and A2M : Role of BRICS K M Gopakumar TWN.

Essential Medicines and the University Challenge: Promoting Local Research for Global Impact For more information, please visit: UAEM home page:

| International Clinical Trials Registry Platform1 Innovation of New Antibiotics WHO Technical Briefing Seminar Zafar Mirza 04 November 2014 WHO, Geneva.

TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.

MSF Access Campaign Started in 1999 Rooted in field experience Three Pillars: –Overcoming Barriers –Research and Development for Drugs for Neglected Diseases.

Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.

The future of commissioning 23 June 2015.

Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.

Pharmacology & Prescribing Essential Drugs: Practical Guidelines International Drug Price Indicator Guide Merck Manuals WHO Model List of Essential Drugs.

Sustainable Approaches to Opening Access to Medical Inventions James Love Wizards of OS Berlin 15 Sept 06.

© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.

Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.

Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.

What do we mean with ‘ there is no access to Paediatric ARV Formulations ’ ?

A Demand Forecasting Tool for Pediatric Antiretroviral Medications November 3, 2004.

Millions of people have a drug problem ! They can not get any !

Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.

Lessons learned from the Global Fund’s Price and Quality Reporting (PQR) database T Patrick Aylward, Sophie Logez, Thuy Huong Ha, Monika Zweygarth, Carmen.

Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”

Patient needs driven Research and Development Agenda in HIV Dr. Felipe Garcia de la Vega MSF Campaign for Access to Essential Medicines.

Section D Free E-journals Access Directory of Open Access Journals BioMed Central PubMed Central HighWire Press PubMed search options.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.

Ellen ‘t Hoen Médecins sans Frontières

COST-EFFECTIVENESS OF THE WORLD HEALTH ORGANIZATION TREATMENT GUIDELINES IN AFRICA Eran Bendavid Philip Grant, Annie Talbot, Douglas Owens, Andrew Zolopa.

Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.

Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.

Sources and prices of newer ARVs: Prospects for Pricing and Availability XVI International AIDS Conference Satellite Session -- August 13, 2006 Médecins.

The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.

Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.

THE TRANS-PACIFIC PARTNERSHIP An overview. History 2005: Trans-Pacific Strategic Economic Partnership Agreement, a free trade agreement, signed by Brunei,

CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

Areas of Work Regulatory System Strengthening Access and Rational Use Blood, Radiological and Pharmaceutical Services.

ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS

How Advocacy can Influence Pricing & Policy

Generic Competition Universities Allied for Essential Medicines

Drug Pricing Policies and Challenges

Pharmacovigilance in Uganda

Forecasting for ARVs medicines

Intellectual Property Rights in Medicines Procurement

Multi-Stakeholder Collaboration in Support of Local Production of Pharmaceuticals (LPP) Mr. Godfrey Keele, MPharm (UNIDO) HRDC Summit, 29 March 2016,

Presentation transcript:

Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières

A sleeping sickness patient, N'dalatando, Angola, 1997

Justice Access to essential medicines as a human right Essential medicines as public goods

Justice

The right of access to essential medicines

Essential medicines as public goods

Some essential medicines still not on the List Overcome intellectual property barriers to access Address R&D crisis for medicines for developing country diseases Maintain the production of essential medicines and secure the market Future challenges for essential medicines

Some essential medicines still not included on the List

Overcome intellectual property barriers to access

The Effects of Generic Competition Stavudine (d4T) + lamivudine (3TC) + nevirapine (NVP): Lowest world prices per patient per year

Address R&D crisis for medicines for developing country diseases

Research for drugs for neglected diseases 1975 to 1999: 1,393 new chemical entities marketed Tropical diseases: 13 Tuberculosis: 3

Maintain the production of essential medicines and secure the market